{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:37:45Z","timestamp":1761100665023},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,1,5]],"date-time":"2004-01-05T00:00:00Z","timestamp":1073260800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The aim of this study was to assess the effectiveness and safety of risperidone monotherapy for acute and continuation treatment of mania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Ninety\u2010six DSM\u2010IV acutely manic bipolar patients with a Young mania rating score (YMRS) of 20 or more entered this open, multicentre, 6\u2010month study. Efficacy was assessed with the YMRS, the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGI). Safety was assessed with the UKU side effect rating scale and with the Hamilton depression rating scale, for the assessment of a switch to depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>80 patients (83.3%) completed the study. Using the last\u2010observation\u2010carried\u2010forward analysis, risperidone produced highly significant improvements (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) on the all efficacy measures from weeks 1 (YMRS) and 4 (PANSS and CGI) onwards, for a 6\u2010month period. There was a significant increase in extrapyramidal side\u2010effects by week 4 (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) and a significant decrease at the 6\u2010month endpoint (<jats:italic>p<\/jats:italic>\u2009=\u20090.027). Risperidone did not induce depressive symptoms, as mean HDRS scores actually improved (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and exacerbation of mania was rare (<jats:italic>n<\/jats:italic>\u2009=\u20094, 4.2%). The mean dose of risperidone was 4.2\u2009mg\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Monotherapy with risperidone is effective and well tolerated in acute and continuation treatment of mania. The results should be confirmed in randomized, double\u2010blind clinical trials. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.556","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T08:01:13Z","timestamp":1073376073000},"page":"41-45","source":"Crossref","is-referenced-by-count":25,"title":["Acute and continuation risperidone monotherapy in mania"],"prefix":"10.1002","volume":"19","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteve","family":"Brugu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Goikolea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"S\u00e1nchez\u2010Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Reinares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Comes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Colom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anabel","family":"Mart\u00ednez\u2010Ar\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Benabarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,5]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(02)73419-2"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0802"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"e_1_2_1_5_1","unstructured":"EerdekensM KarchnerK GrossmanF KramerM.2003.Risperidone monotherapy in acute bipolar mania. Poster presented atI WPA Congress on Diagnosis in Psychiatry Vienna June 19\u201322."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199711000-00006"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0907"},{"key":"e_1_2_1_8_1","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy W","year":"1976"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","unstructured":"HirschfeldR KeckPE KarcherK KramerM GrossmanF VietaE.2003.Rapid antimanic effect of risperidone monotherapy: a 3\u2010week multicenter double\u2010blind placebo\u2010controlled trial. Poster presented atThe Third International Expert Review of Bipolar Disorders. Munich April 6\u20138.","DOI":"10.1176\/appi.ajp.161.6.1057"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_1_14_1","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double blind randomised controlled study","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_15_1","first-page":"249","article-title":"Risperidone in the treatment of mania","volume":"57","author":"Tohen M","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_16_1","first-page":"491","article-title":"Treatment of disphoric mania with risperidone","volume":"10","author":"Vieta E","year":"1995","journal-title":"Hum Psychopharmacol Clin"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00481-5"},{"key":"e_1_2_1_19_1","unstructured":"VietaE KhannaS LyonsB GrossmanF KramerM.2003.Risperidone monotherapy in acute bipolar mania. Poster presented atThe Third International Expert Review of Bipolar Disorders. Munich April 6\u20138."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.556","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:50:24Z","timestamp":1700254224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/hup.556"],"URL":"https:\/\/doi.org\/10.1002\/hup.556","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}